Adicet Bio, Inc. announced positive clinical biomarker data for its ADI-001 therapy, showing significant CAR T cell activation and complete B cell depletion in secondary lymphoid tissue, with a mean exposure of 236,701 CAR T cells per million in the Phase 1 GLEAN trial.